Neurofibromatosis Type 2 Market Growth Accelerated by Better Diagnostics and Targeted Therapy Development 2025-2033 | AstraZeneca Plc, OCEAN PHARMACEUTICAL, Vivace Therapeutics

Global Neurofibromatosis Type 2 Market reached US$ 3.52 billion in 2024 and is expected to reach US$ 7.08 billion by 2031, growing at a CAGR of 14.48% during the forecast period 2024-2031.

Neurofibromatosis Type 2 Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/neurofibromatosis-type-2-market?ophp

Neurofibromatosis Type 2 (NF2) is a rare genetic disorder characterized by benign tumors on nerves, especially the auditory nerves, leading to hearing loss and neurological complications. The treatment market is emerging with growing clinical trial activity, targeted biologics, and supportive surgical and hearing restoration therapies.

Neurofibromatosis Type 2 Market Competitors Overview:

Manus Aktteva Biopharma LLP, AstraZeneca Plc, OCEAN PHARMACEUTICAL, Vivace Therapeutics, Ikena Oncology, Inc., Recursion Pharmaceuticals Inc. among others

Important Industry Updates of 2023, 2024 and 2025:

✅ In March 2025, the U.S. Congress eliminated the entire CDMRP NF Research Program, which had provided approximately $25 million in 2024 alone.

Pipeline Progress - Emerging Therapies

➤ REC‐2282 (Recursion): an oral HDAC inhibitor targeting NF2-mutated meningiomas, entered a Phase 2/3 trial in Q2 2022. The drug holds Fast Track and Orphan Drug designation in the U.S. and EU .

➤ Selumetinib (AstraZeneca): a MEK1/2 inhibitor, currently under evaluation in a Phase II trial for NF2-related tumors, representing one of the most advanced pipeline candidates.

➤ Additional preclinical and early-stage NF2 assets include TEAD inhibitors, designed to target Hippo-pathway dysregulation.

Methodology and Scope

The Neurofibromatosis Type 2 Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurofibromatosis-type-2-market?ophp

Neurofibromatosis Type 2 Market Segments Overview:

∎ By Tumor Type (Vestibular Schwannomas, Meningiomas, Other Tumors)
∎ By Treatment Type (Surgery (Tumor Removal, Stereotactic Radiosurgery, Others), Radiation Therapy), Drug Therapy (Lapatinib, Selumetinib, Bevacizumab, Others), Others)
∎ By End-User (Hospitals, Cancer Centers, Others)

Regional Overview for Neurofibromatosis Type 2 Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=neurofibromatosis-type-2-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.